JP2015517466A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517466A5
JP2015517466A5 JP2015510380A JP2015510380A JP2015517466A5 JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5 JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015510380 A JP2015510380 A JP 2015510380A JP 2015517466 A5 JP2015517466 A5 JP 2015517466A5
Authority
JP
Japan
Prior art keywords
rnai agent
composition
kras
strand
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/038847 external-priority patent/WO2013166004A2/en
Publication of JP2015517466A publication Critical patent/JP2015517466A/ja
Publication of JP2015517466A5 publication Critical patent/JP2015517466A5/ja
Pending legal-status Critical Current

Links

JP2015510380A 2012-05-02 2013-04-30 Ｋｒａｓ関連疾患を処置するための有機組成物 Pending JP2015517466A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261641588P 2012-05-02 2012-05-02
US61/641,588 2012-05-02
PCT/US2013/038847 WO2013166004A2 (en) 2012-05-02 2013-04-30 Organic compositions to treat kras-related diseases

Publications (2)

Publication Number Publication Date
JP2015517466A JP2015517466A (ja) 2015-06-22
JP2015517466A5 true JP2015517466A5 (enExample) 2016-06-23

Family

ID=48366565

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510380A Pending JP2015517466A (ja) 2012-05-02 2013-04-30 Ｋｒａｓ関連疾患を処置するための有機組成物

Country Status (12)

Country Link
US (3) US20150238515A1 (enExample)
EP (3) EP3736333A1 (enExample)
JP (1) JP2015517466A (enExample)
KR (1) KR20150004414A (enExample)
CN (2) CN104583406A (enExample)
AU (5) AU2013256471A1 (enExample)
BR (1) BR112014027337A2 (enExample)
CA (2) CA2872304C (enExample)
EA (1) EA201492004A1 (enExample)
HK (1) HK1206387A1 (enExample)
MX (1) MX2014013367A (enExample)
WO (1) WO2013166004A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201620525A (zh) * 2014-03-14 2016-06-16 波士頓生醫公司 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法
SG10201911695SA (en) 2014-05-14 2020-01-30 Targimmune Therapeutics Ag Improved polyethyleneimine polyethyleneglycol vectors
US11180759B2 (en) * 2016-01-19 2021-11-23 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS
US10858656B2 (en) * 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
KR102543645B1 (ko) * 2016-07-20 2023-06-16 주식회사 지씨지놈 유전성 발달장애 진단용 조성물 및 이의 용도
CN118638788A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
JP2022535849A (ja) * 2019-06-05 2022-08-10 サウザーン リサーチ インスチチュート チアラビンベースおよびチアラビンのプロドラッグベースの治療
EP4058152A4 (en) * 2019-11-14 2024-05-08 The Board of Regents of the University of Oklahoma PROSTATE CANCER TREATMENTS USING OLIGONUCLEOTIDES INTERFERENCE
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2021207339A1 (en) * 2020-04-07 2021-10-14 The University Of North Carolina At Chapel Hill Methods and compositions using rna interference and antisense oligonucleotides for inhibition of kras
US20240392293A1 (en) * 2021-09-02 2024-11-28 Molecular Axiom, Llc Compositions and methods for modulating kras expression
MX2024003266A (es) 2021-09-16 2024-04-03 Avidity Biosciences Inc Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
WO2024155770A2 (en) * 2023-01-18 2024-07-25 Molecular Axiom, Llc Compositions for modulating kras expression and uses thereof
EP4669752A1 (en) * 2023-02-22 2025-12-31 Altamira Therapeutics AG KRAS COMPOSITIONS AND INHIBITION METHODS FOR THE TREATMENT OF A DISEASE
WO2026026715A1 (zh) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 一种用于抑制KRAS基因表达的siRNA及其修饰物与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
WO2001068836A2 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6680068B2 (en) 2000-07-06 2004-01-20 The General Hospital Corporation Drug delivery formulations and targeting
WO2002100435A1 (en) 2001-06-11 2002-12-19 Centre Hospitalier Universitaire De Montreal Compositions and methods for enhancing nucleic acid transfer into cells
DE60236520D1 (de) 2001-08-16 2010-07-08 Univ Pennsylvania Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
JP2006512906A (ja) 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
ATE465255T1 (de) 2002-11-26 2010-05-15 Univ Massachusetts Verabreichung von sirnas
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
CA2536333C (en) 2003-08-28 2013-01-08 Jan Weiler Interfering rna duplex having blunt-ends and 3'-modifications
WO2005044981A2 (en) * 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP1714970A1 (en) * 2005-04-22 2006-10-25 Universität des Saarlandes Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity
WO2007051303A1 (en) 2005-11-02 2007-05-10 Protiva Biotherapeutics, Inc. MODIFIED siRNA MOLECULES AND USES THEREOF
AU2007229161B2 (en) 2006-03-23 2012-07-12 Roche Innovation Center Copenhagen A/S Small internally segmented interfering RNA
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US8809514B2 (en) * 2006-09-22 2014-08-19 Ge Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by RNA interference
JP2010519912A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｒａｓ遺伝子の発現を抑制するための核酸化合物およびその使用
BRPI0811170B8 (pt) 2007-05-22 2021-05-25 Arcturus Therapeutics Inc oligonucleotídeos de rna e complexos de rna substituídos por hidroximetila
EP2190995A2 (en) * 2007-09-18 2010-06-02 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
JP5697988B2 (ja) 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
WO2010006237A2 (en) * 2008-07-11 2010-01-14 Alnylam Pharmaceuticals, Inc. Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
ES2628144T3 (es) * 2009-04-03 2017-08-01 Dicerna Pharmaceuticals, Inc. Métodos y composiciones para la inhibición específica de KRAS por RNA bicatenario asimétrico
AU2010334911A1 (en) 2009-12-23 2012-07-12 Novartis Ag Lipids, lipid compositions, and methods of using them
EP2544671A2 (en) * 2010-03-12 2013-01-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pharmaceutical composition for the treatment of chlamydial infection

Similar Documents

Publication Publication Date Title
JP2014525435A5 (enExample)
JP7728923B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2015503608A5 (enExample)
JP2023093644A (ja) アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP7118063B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2016511256A5 (enExample)
JP2013525332A5 (enExample)
JP2013514321A5 (enExample)
JP2022528725A (ja) 筋ジストロフィーを治療するための組成物
JP2018512060A5 (enExample)
JP2019504112A5 (enExample)
HRP20201200T1 (hr) OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK
JP7291418B2 (ja) Ｐｃｓｋ９を標的としたアンチセンス核酸
JP2014518612A5 (enExample)
US9080175B2 (en) Organic compositions to treat Beta-ENaC-related diseases
JP2011517676A5 (enExample)
JP2023539341A (ja) Ｄｕｘ４阻害剤およびその使用方法
JP2016513976A5 (enExample)
US20200190517A1 (en) Organic compositions to treat epas1-related diseases
JP2021526017A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
JP2019503199A5 (enExample)
AU2016204832A1 (en) Organic compositions to treat KRAS-related diseases
JP2021521794A (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
CN108138180A (zh) 用于治疗皮肤t细胞淋巴瘤（ctcl）的mir-155抑制剂
TW202300647A (zh) 用於治療多囊腎病之組成物